Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/18/10 → 9/30/12 |
Funding
- Novo Nordisk Pharmaceuticals Inc: $73,479.00
An Extension to Trial NN1250-3583 Comparing Safety and Efficacy of NN1250 With InsulinGlargine, Both With Insulin Aspart as Meal-Time Insulin, in Type 1 Diabetes
- Karounos, Dennis (PI)